potently overcome most imatinib resistance mechanisms. 10 However, whether TKI alone can kill all the cancerous cells, which is a prerequisite for curing CML, is in doubt because TKIs are much less effective against quiescent CML stem cells. 11, 12 Bone marrow (BM) is a hypoxic tissue, particularly at the epiphysis, which is distant from the BM arterial blood supply (Supplementary Figure 1) . 13 In addition, leukemic cells are more hypoxic than normal cells in the BM because of cell crowding, due to accelerated cell growth, as well as the anemia that commonly accompanies the progression of leukemia. 14, 15 The oxygen supply is frequently inadequate for the level of oxygen consumption in the microenvironment of rapidly proliferating cancer cells. 16 Although not identified conclusively until today, Bcr-Abl þ CML stem cells are in a quiescent state in the niche. In addition, human primary leukemic cells expressing CD34 inoculated into immunodeficient mice initially populate the hypoxic epiphysial region. 17 Thus, it is likely that quiescent leukemic cells predominantly reside in and survive in a hypoxic BM environment.
Most cancer cells that have adapted to hypoxia are resistant to a variety of cell death stimuli. 18, 19 A shift in energy production from aerobic to anaerobic respiration causes a number of dramatic changes in cell phenotype, including the accumulation of hypoxia-specific by-products, alterations in the cell cycle, and resistance to chemotherapeutic drugs. Given these observations, we hypothesized that adaptation to hypoxia is one of the causes of minimal residual disease in patients treated with Abl TKIs. The molecular mechanisms of adaptation to hypoxia may provide new targets for cancerspecific therapies that are effective against cells in hypoxic microenvironments.
Results
Bcr-Abl þ cells in the BM survive in hypoxic conditions. Four NOD/SCID/g c null (NOG) mice were inoculated with 1.0 Â 10 6 K562 cells, a human cell line established from a Bcr-Abl þ CML patient. Mice were killed 35 days after transplantation and examined for engraftment. Viable K562 engraftments in the BM were identified in three of the four mice. In the mouse with failed engraftment (Figure 1a) , only a small population of normal cells were positive for pimonidazole, which specifically accumulates in hypoxic cells (o1.3% O 2 concentration) along the endosteum (Figure 1b ). Liver cells from this were also negative for pimonidazole ( Figure 1c ). The transplanted K562 cells initially populated the epiphysis in recipient NOG mice. The engrafted cells were easily distinguished from normal mouse hematopoietic cells by their larger size and prominent nuclei (Figure 1d ). Immunohistochemical staining with an antibody specific for human Ki-67, which is expressed in actively cycling but not quiescent cells (G 0 ) (Figure 1e) , 22 also confirmed that K562 cells were successfully engrafted. The area of Ki-67-positive staining was in good agreement with the engraftment area estimated by cell morphology (Figures 1d  and e) . Although most of the engrafted cells were positive for Ki-67, a few cells were not (Supplementary Figure 2) , suggesting that some engrafted K562 cells may have entered a quiescent G 0 state. 22 The majority of engrafted K562 cells were also positively labeled by pimonidazole ( Figure 1f ). Next, we engrafted NOD/SCID mice with primary Bcr-Abl þ cells from a Ph þ acute lymphoblastic leukemia (Ph HA-CML cell lines. To generate hypoxia-adapted (HA)-CML cells, four CML-derived cell lines, K562, KCL22, BV173 and MYL, were continuously cultured under hypoxic conditions (1.0% O 2 ). Most cells were arrested in the G 1 phase of the cell cycle 2 days after transfer to hypoxic conditions as shown by an increase in the percentage of sub-G 1 cells in all four cell lines. Most of these cells underwent apoptosis within 7 days, and none of the BV173 or MYL cells survived more than 7 days (Supplementary Figure 3) . In contrast, a small fraction of K562 and KCL22 cells survived in 1.0% O 2 for more than 7 days. We isolated these HA sublines of K562 and KCL22 (termed K562/HA and KCL22/ HA, respectively), and these cells continued to proliferate under 1.0% O 2 for more than a year (Figures 2a and b) . The (Figures 2a and b) , the growth of the HA-CML cells was still much slower than their respective parental cell lines (Figure 2c) .
We next examined the cytotoxic effects of the Abl TKIs, including imatinib, dasatinib and INNO-406, on K562, K562/ HA, KCL22 and KCL22/HA cells. K562/HA cells were highly resistant to all Abl TKIs examined, compared with the parental K562 cells (Figure 2d , Figure 2g ). In contrast to K562 and K562/HA cells, there were no differences between KCL22 and KCL22/HA cells ( Figure 2g ). These findings suggest that adaptation to hypoxia may have some impact on the mechanisms for executing apoptosis, although further investigation will be required to confirm this hypothesis. Luc-EGFP cells in NOG mice were monitored using in vivo imaging (Figure 4a) . Despite the lower level of bioluminescence in K562/HA Luc-EGFP cells in culture, there were no significant differences in total photon emission between K562
Luc-EGFP -and K562/HA Luc-EGFP -engrafted mice before day 34. After day 34, the total photon emission of K562/HA Luc-EGFP -engrafted mice increased much more sharply than that of K562 Luc-EGFP mice (Figure 4b ). In addition, K562/HA Luc-EGFP -transplanted mice died significantly earlier than did K562
Luc-EGFP mice (Figure 4c ). These results indicate that K562/HA Luc-EGFP cells engrafted more efficiently in NOG mice than did the parental K562
Luc-EGFP cells. To investigate why K562/HA Luc-EGFP cells engrafted more efficiently, we examined the cell cycle distribution of K562 and K562/HA cells. The percentages of cells in G 0 in K562 and K562/HA cells were 0.87 þ 0.58 and 4.9 þ 2.1%, respectively, indicating that the K562/HA grafts included more quiescent cells than did the parental line (Figures 4d and e) . Next, we examined the expression of c-kit, Tie-2, CXCR4, Notch, N-cadherin, VLA-4, LFA-1 and CD44, all of which have been reported to indicate stemness. 23 There was no difference in the expression levels of these proteins in K562/HA or KCL22/ HA cells and the respective parental cell lines (data not shown). Interestingly, both HA cell lines expressed higher levels of b-catenin, which is thought to be important for (Figure 4f) . 24 In addition, the K562/HA cell line contained more cells with the side population marker for cancer stem cells (Figure 4g) . 25 These findings suggest that the adaptation to hypoxia induces putative stem/ progenitor cell-like characteristics in Bcr-Abl þ cells.
Effect of Glo-I inhibitors on HA-CML cells. S-p-bromobenzyl glutathione cyclopentyl diester (BBGC) (Figure 3f ) is a specific cell-permeable inhibitor of Glo-I, 26 and 2-crotonyloxymethyl-4,5,6-trihydroxycylohex-2-enone (COTC) (Figure 3g ) is an inhibitor of Glo-I and glutathione. 27 Recently, methyl-gerfelin (Supplementary Figure 7a) was also identified as a Glo-I inhibitor. 28 Although HA-CML cells were resistant to the cytotoxic effects of Abl TKIs and alkylating agents (Figures 2d  and e, Table 1 ), BBGC, COTC and methyl-gerfelin were more strongly cytotoxic in K562/HA and KCL22/HA cells than in the parental cell lines (Figures 5a-d, Supplementary  Figures 7b and c) .
To determine the mechanism of cell death induced by BBGC, we examined Annexin V staining (Supplementary Figures 8e-h ). The proportion of cells undergoing apoptosis was greater in the BBGC-and COTCtreated K562/HA and KCL22/HA cells than in the parental cells (Supplementary Figures 9a-d) . These results indicate that HA-CML cells were dependent on Glo-I activity for survival under hypoxic conditions, whereas the parental cells, cultured in normoxic conditions, were not dependent on Glo-I activity.
To evaluate the in vivo antileukemic activity of BBGC, we treated NOG mice inoculated with K562 Luc-EGFP or K562/ HA Luc-EGFP cells with BBGC. BBGC had no apparent effect on the survival of K562
Luc-EGFP -engrafted mice (Figure 5e ).
However, it significantly prolonged the survival of K562/ HA Luc-EGFP -transplanted mice (Figure 5f ). The body weight of BBGC-treated mice did not decrease during the course of treatment (data not shown). These findings indicate that BBGC has potent antileukemic effects in vivo, and preferentially targets CML cells with higher Glo-I activity, with minimal associated toxicity.
Discussion
Abl TKIs can induce apoptosis only in actively proliferating Bcr-Abl þ cells, making these drugs much less active against CML stem cells, which are predominantly in a quiescent state. 10, 11, 29 Hypoxia favors the self-renewal of normal hematopoietic stem cells, 30 and resistance to hypoxia is one of the defining features of leukemic stem cells. 31 Therefore, it may be more important to search for new antileukemic agents that target quiescent CML stem cells residing in the hypoxic BM milieu. To this end, we have established two HA-CML sublines (Figures 2a-c) . Previously, investigators have studied the role of hypoxia in leukemia using relatively shortterm assays. [30] [31] [32] Our results suggest that transient hypoxia may not adequately mimic the physiological environment of CML cells (Figure 3e ). Furthermore, in the mouse CML xenograft model, the oxygen concentration of engrafted leukemic cells in the BM was o10 mm Hg (B1.3% O 2 ) (Figure 1f) . Interestingly, the HA-CML cells exhibited characteristics similar to CML stem cells, including greater numbers of cells in a dormant, side population fraction, higher b-catenin expression, resistance to Abl TKIs and higher transplantation efficiency (Figures 2d, e and 4 , Supplementary Figures 8 and 9) .
The level of Bcr-Abl phosphorylation was lower in HA-CML cells, which may explain why those cells are less sensitive to Abl TKIs (Figure 2f ). Giuntoli et al. 32 have also reported that the hypoxic selection of CML cells resulted in decreased cell sensitivity to imatinib and activation of Bcr-Abl-independent survival signaling pathways. Erk, a downstream effector of Bcr-Abl, was also less phosphorylated in HA-CML cells compared with parental cells, whereas the levels of p-Akt and p-Stat5 were similar (Figure 2f ). These observations suggest that alternative mechanisms of activation exist for these signaling molecules in HA-CML cells. 33 In addition to the phosphorylation status of Bcr-Abl, the sensitivity to antileukemic agents depends on the balance of pro-and antiapoptotic molecules. 8 Akt pro-survival effects have been reported to be dependent on the first step in glycolysis. 34 However, Glo-1 induction in HA-CML cells was not directly controlled by Akt because Akt phosphorylation was unchanged in both HA cell lines (Figure 2f) . The adaptation to hypoxia may also alter the status of Bcl-2 family members, because the expression levels of several proteins were altered in K562/HA cells. However, there were no changes in KCL22/HA cells. As the parental KCL22 cells are intrinsically resistant to imatinib and exhibit very high Bcl-2 expression, alterations in Bcl-2 family proteins may not be obvious. Further experiments will be required to clarify the hypoxia-induced changes.
We tried to identify a specific target in HA-CML cells that could be inhibited by small molecules with therapeutic potential. The dependence on glycolysis-mediated ATP production for uncontrolled cellular growth under limited O 2 conditions is a hallmark of malignant cells (Figure 3b) . 35, 36 Reduced ATP production (Figure 3a) , as well as increased glucose consumption and lactate production (Supplementary Figure 4) in HA-CML cells, suggested that there was preferential utilization of glycolysis for ATP production in these cells. We focused on the components of glycolysis to identify leukemia cell targets that would circumvent drug resistance acquired through adaptation to hypoxia. 37, 38 Glo-I is an enzyme that detoxifies methylglyoxal, a cytotoxic a-oxoaldehyde side product of glycolysis. Accumulation of methylglyoxal damages cells through multi-base DNA deletions and base-pair substitutions. The overexpression of Glo-I induces drug resistance to alkylating agents in leukemia as well as other solid tumors. 26, 39 Glo-I activity was elevated in both K562/HA and KCL22/HA cells (Figures 3c and d) , possibly because of their increased dependence on glycolysis during adaptation to hypoxia. Both K562/HA and KCL22/HA cells were more sensitive to cell killing by Glo-I inhibitors, indicating that these cells are indeed dependent on Glo-I activity for survival under hypoxic conditions (Figures 5a-d,  Supplementary Figures 7b, c, 8 and 9 ).
All the Glo-I inhibitors examined were effective for killing HA-CML cells in vitro. We selected BBGC for in vivo analysis because BBGC was the most potent compound in vitro, and because BBGC has previously been used against lung cancer in vivo. 40 As engrafted K562 cells survive in the hypoxic environment of the BM (Figure 1f) , we expected that BBGC would be effective against the parental K562
Luc-EGFP cells, even if Glo-I activity in these cells was low. However, BBGC had no effect on the survival of K562
Luc-EGFP -engrafted mice (Figure 5e ). This result may be due to the time differences between Glo-I induction by hypoxia and administration of BBGC. BBGC was administered from day 1 to day 11 after transplantation, whereas, in in vitro cultures, Glo-I was not induced until 21 days after the initiation of hypoxia (Figure 3e) . Intriguingly, BBGC significantly prolonged the survival of K562/HA Luc-EGFP -engrafted mice compared with untreated mice (Figure 5b) . Thus, BBGC may be a promising therapeutic agent for use against CML cells with high Glo-I activity, which also more frequently accompanies the quiescent status. As the Abl inhibitor imatinib is currently the drug of choice for CML treatment, we examined the combined effects of BBGC with imatinib in vitro. BBGC augmented the effects of imatinib in killing CML cells in vitro (Supplementary Figure 10) .
In conclusion, the survival of engrafted leukemic cells in the BM under severe hypoxia depends on the induction of Glo-I activity, and adaptation to hypoxia seems to result in the acquisition of Abl TKI resistance in CML cells. Glo-I inhibitors were much more effective against HA-CML cells than parental cells both in vitro and in vivo. These findings indicate the importance of the hypoxic environment for maintaining quiescent CML cells, and suggest that Glo-I is a novel target for CML treatment.
Materials and Methods
Reagents and cell lines. The Glo-I inhibitors, BBGC, COTC and methylgerfelin, were synthesized and purified as previously described. [26] [27] [28] The K562 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). The other CML-derived cell lines (KCL22, BV173 and MYL) were kindly provided by Dr Tadashi Nagai (Jichi Medical School, Tochigi, Japan), Dr Oliver G Ottmann (Frankfurt University, Frankfurt, Germany) and Dr Hideo Tanaka (Hiroshima University, Hiroshima, Japan), respectively. The CML cell lines were maintained in RPMI-1640 supplemented with 10% fetal calf serum (Vitromex, Vilshofen, Germany) at 371C in a humidified atmosphere of 20% O 2 , 5% CO 2 and 75% N 2 . CML cells were subjected to continuous culture in 1.0% O 2 (7.2 mm Hg), 5% CO 2 and 94% N 2 , and HA subclones of K562 (K562/HA) and KCL22 (KCL22/HA) were selected and maintained in suspension in low O 2 conditions for more than 6 months. Parental K562 and K562/HA cells were cotransfected with pGL3, a control luciferase (Luc) reporter vector (Promega, Madison, WI, USA) and pCAG.egfp.neo using the Nucleofector Kit V, protocol T-03 (Amaxa AG, Cologne, Germany). Stable transfectants (K562 Luc-EGFP and K562/HA Luc-EGFP ) were selected by culturing in medium containing G418 (1 mg/ml, Sigma Aldrich, Tokyo, Japan) and isolated by agarose gel cloning assays. Human primary Bcr-Abl þ leukemic cells were obtained from patients with informed consent, according to the Declaration of Helsinki.
In vivo engraftment of CML cells and histological analysis. Animal studies were performed in accordance with the guidelines of the Institutional Review Board for animal studies at Kyoto University. To evaluate the oxygen status of engrafted leukemic cells, 1.0 Â 10 6 cells were injected into sublethally irradiated (2 Gy) male NOG or NOD/SCID mice at 6-8 weeks of age. At 35 days (NOG mice) or 50 days (NOD/SCID mice) post-inoculation, the mice were injected intraperitoneally with pimonidazole hydrochloride (Pimo, Chemicon, Temecula, CA, USA) (60 mg/kg), and 60 min later, the animals were killed and the femur and liver removed. Tissues were subjected to hematoxylin-eosin staining and immunohistochemical analysis using anti-Pimo (Chemicon) and antihuman Ki67 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies, and examined by microscopy. In vivo, leukemia cell proliferation was detected by monitoring luciferase expression using an in vivo imaging system (Xenogen, Berkeley, CA, USA), as previously described. 41 For survival analysis, time of death was determined either by spontaneous death, or by date of euthanasia due to pain or suffering, according to established criteria. We also confirmed the oxygen concentration of primary Bcr-Abl þ leukemic cells that were obtained from a Ph ) were transplanted into four NOD/SCID mice, which were killed 50 days after transplantation, and the BM sections were stained as above.
Cell death. Cell viability was measured by incorporation of propidium iodide (PI). Mitochondrial transmembrane potential (Dcm) was determined by staining with 3,3 0 -dihexyloxacarbocyanine iodide (Molecular Probes, Eugene, OR, USA), as previously described. 9 For analysis of DNA content, cells were fixed with ice-cold 70% ethanol and then incubated with PI as previously described. 42 The percentage of cells that incorporated PI, the Dcm, and the percentage of cells in sub-G 1 of the cell cycle were determined by FACS using the CellQuest software (Becton Dickinson, San Jose, CA, USA).
Western blot analysis. Proteins were separated by SDS-PAGE and then electroblotted onto a Hybond-PDVF membrane (Amersham Biosciences, Uppsala, Sweden). The membranes were incubated with 5% (wt/vol) nonfat dry milk in Immunoreactive proteins were detected with horseradish peroxidase-conjugated secondary antibodies using enhanced chemiluminescence (ECL Advance, Amersham Biosciences).
Measurement of Glo-I activity. Cells were lysed in PBS containing 1 mM phenylmethylsulfonyl fluoride by freezing and thawing, followed by sonication. The lysates were centrifuged at 12 000 Â g for 20 min and the supernatant was used as the cytosolic fraction. The Glo-I assay was performed in 0.1 M sodium phosphate (pH 7.0), 7.9 mM methylglyoxal (Sigma), 1 mM GSH and 14.6 mM MgSO 4 at 25 1C. An increase in absorbance at 240 nm because of the formation of S-D-lactoylglutathione was measured using a temperature-controlled spectrophotometer (Beckman Coulter, Brea, CA, USA, DU640).
ATP assay. ATP levels were measured using an ATP assay kit (TOYO INK, Tokyo, Japan), according to the manufacturer's instructions.
Measurement of glucose consumption and lactate production. Cells were suspended in fresh culture medium. After 6 h, the cells were collected by centrifugation and resuspended in 5 ml of RPMI at a density of 2 Â 10 5 cells/ml. Cells were incubated for 24 h, and the culture medium was collected for measurement. Glucose levels were determined using a glucose assay kit (GO, Sigma). Glucose consumption was determined from the difference in glucose concentration compared with the starting medium. Lactate levels were determined using a lactate assay (F-kit L-lactate, JK International, Tokyo, Japan).
Determination of quiescent cells. Numbers of quiescent leukemic cells (in G 0 phase) were determined by double staining with Ki-67 and 7-AAD as previously described. 43 Briefly, 1 Â 10 6 K562 or K562/HA cells were fixed in ice-cold 70% EtOH for at least 12 h, and then resuspended in 100 ml PBS. Cells were stained with 20 ml Ki-67 antibody (BD Biosciences) and incubated for 30 min at RT. Subsequently, 20 ml 7-AAD (BD Biosciences) was added, and the cells were resuspended in 500 ml PBS with 1% FBS and analyzed by FACS. Three independent analyses were performed.
BBGC treatment of CML mice. NOG mice 6-8 weeks of age were sublethally irradiated (2 Gy) and inoculated with 1.0 Â 10 6 K562/HA Luc-EGFP or K562/HA Luc-EGFP cells by intravenous tail vein injection. Therapeutic treatments (seven mice per group) were started 1 day (day 1) after transplantation. To prepare the BBGC solution, BBGC dissolved in cremophor EL/DMSO (1 : 1) was diluted to 10 mg/ml using DMSO and PBS. Within each group, half of the mice were administered EL/DMSO only (vehicle controls), and the remainder were administered 10 mg/kg BBGC on days 1 through 4, and days 8 through 11 after transplantation. For survival analysis, the time of death was determined either by spontaneous death or by date of euthanasia due to pain or suffering, according to established criteria.
Statistical analysis. Survival curves were drawn using the Kaplan-Meier method and compared using the log-rank test. P-values were derived from twosided tests and a P-value o0.05 was considered statistically significant.
